Conclusions
BREAST CANCER
In conclusion, amcenestrant demonstrated pharmacodynamic activity in women with ER+/HER2− breast cancer, with marked reductions in Ki67 and hormone receptor H-scores. Changes in ER H-score confirm that amcenestrant demonstrates potent ER target engagement and degradation. Additionally, amcenestrant had a favorable safety profile at both dose levels.However, we did not observe any advantage of amcenestrant over letrozole, a finding consistent with interim data from the Phase 3 AMEERA-5 trial (amcenestrant versus letrozole, both in combination with palbociclib, as first-line treatment for advanced or metastatic ER+/HER2− breast cancer) [